Gaucher Disease: Transcriptome Analyses Using Microarray or mRNA Sequencing in a Gba1 Mutant Mouse Model Treated with Velaglucerase alfa or Imiglucerase

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Dasgupta, Nupur ^a   Xu, You Hai ^a,b   Oh, Sunghee ^a,b   Sun, Ying ^a,b   Jia, Li ^c   Keddache, Mehdi ^a,b   Grabowski, Gregory A ^a,b  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; HEME; IMIGLUCERASE; MESSENGER RNA; TRANSCRIPTOME; VELAGLUCERASE ALFA;

ALLELE; ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME REPLACEMENT; GAUCHER DISEASE; GBA1 GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENETIC DIFFERENCE; INTERMETHOD COMPARISON; LIVER; LUNG; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PORPHYRIN METABOLISM; RNA SEQUENCE; SPLEEN; TRANSCRIPTOMICS; VALIDATION PROCESS;

ANIMALS; CELL CYCLE; CELL PROLIFERATION; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, MESSENGER; TRANSCRIPTOME;

EID: 84885036224     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074912     Document Type: Article

References (84)

1. Grabowski GA, Petsko GA, Kolodny EH (2010) Gaucher Disease. In: D. Valle ALB, B Vogelstein, K.W Kinzler, S.E Antonarakis, and A Ballabio, editor. Metabolic and Molecular Bases of Inherited Disease (OMMBID Mark II) New York: McGraw-Hill Companies, Inc.
2. Guggenbuhl P, Grosbois B, Chales G, (2008) Gaucher disease. Joint Bone Spine 75: 116-124.
3. Pastores GM, Sibille AR, Grabowski GA, (1993) Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 82: 408-416.
4. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, et al. (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122: 33-39.
5. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160: 2835-2843.
6. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, et al. (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113: 112-119.
7. Xu YH, Sun Y, Barnes S, Grabowski GA, (2010) Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. PLoS One 5: e10750.
8. Marshall J, McEachern KA, Chuang WL, Hutto E, Siegel CS, et al. (2010) Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis 33: 281-289.
9. Van Patten SM, Hughes H, Huff MR, Piepenhagen PA, Waire J, et al. (2007) Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology 17: 467-478.
10. McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, et al. (2007) A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91: 259-267.
11. McEachern KA, Nietupski JB, Chuang WL, Armentano D, Johnson J, et al. (2006) AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease. J Gene Med 8: 719-729.
12. Myerowitz R, Mizukami H, Richardson KL, Finn LS, Tifft CJ, et al. (2004) Global gene expression in a type 2 Gaucher disease brain. Mol Genet Metab 83: 288-296.
13. Hong YB, Kim EY, Jung SC, (2004) Down-regulation of Bcl-2 in the fetal brain of the Gaucher disease mouse model: a possible role in the neuronal loss. J Hum Genet 49: 349-354.
14. Xu YH, Jia L, Quinn B, Zamzow M, Stringer K, et al. (2011) Global gene expression profile progression in Gaucher disease mouse models. BMC Genomics 12: 20.
15. Friedman B, Vaddi K, Preston C, Mahon E, Cataldo JR, et al. (1999) A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease. Blood 93: 2807-2816.
16. Brumshtein B, Salinas P, Peterson B, Chan V, Silman I, et al. (2010) Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology 20: 24-32.
17. Dvir H, Harel M, McCarthy AA, Toker L, Silman I, et al. (2003) X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep 4: 704-709.
18. Marioni JC, Mason CE, Mane SM, Stephens M, Gilad Y, (2008) RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. Genome Res 18: 1509-1517.
19. Lynch M, Fitzgerald C, Johnston KA, Wang S, Schmidt EV, (2004) Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth. J Biol Chem 279: 3327-3339.
20. Nilsson R, Schultz IJ, Pierce EL, Soltis KA, Naranuntarat A, et al. (2009) Discovery of genes essential for heme biosynthesis through large-scale gene expression analysis. Cell Metab 10: 119-130.
21. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B, (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5: 621-628.
22. Malone JH, Oliver B, (2011) Microarrays, deep sequencing and the true measure of the transcriptome. BMC Biol 9: 34.
23. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, et al. (2010) Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28: 511-515.
24. Ozsolak F, Milos PM, (2011) RNA sequencing: advances, challenges and opportunities. Nat Rev Genet 12: 87-98.
25. Bradford JR, Hey Y, Yates T, Li Y, Pepper SD, et al. (2010) A comparison of massively parallel nucleotide sequencing with oligonucleotide microarrays for global transcription profiling. BMC Genomics 11: 282.
26. Cloonan N, Forrest AR, Kolle G, Gardiner BB, Faulkner GJ, et al. (2008) Stem cell transcriptome profiling via massive-scale mRNA sequencing. Nat Methods 5: 613-619.
27. Griffith M, Griffith OL, Mwenifumbo J, Goya R, Morrissy AS, et al. (2010) Alternative expression analysis by RNA sequencing. Nat Methods 7: 843-847.
28. Su Z, Li Z, Chen T, Li QZ, Fang H, et al. (2011) Comparing next-generation sequencing and microarray technologies in a toxicological study of the effects of aristolochic acid on rat kidneys. Chem Res Toxicol 24: 1486-1493.
29. Lahiry P, Lee LJ, Frey BJ, Rupar CA, Siu VM, et al. (2011) Transcriptional profiling of endocrine cerebro-osteodysplasia using microarray and next-generation sequencing. PLoS One 6: e25400.
30. Wang L, Feng Z, Wang X, Zhang X, (2010) DEGseq: an R package for identifying differentially expressed genes from RNA-seq data. Bioinformatics 26: 136-138.
31. Robinson MD, McCarthy DJ, Smyth GK, (2010) edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26: 139-140.
32. Anders S, Huber W, (2010) Differential expression analysis for sequence count data. Genome Biol 11: R106.
33. Robinson MD, Smyth GK, (2007) Moderated statistical tests for assessing differences in tag abundance. Bioinformatics 23: 2881-2887.
34. Ponka P, (1997) Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. Blood 89: 1-25.
35. Cotter PD, Baumann M, Bishop DF, (1992) Enzymatic defect in "X-linked" sideroblastic anemia: molecular evidence for erythroid delta-aminolevulinate synthase deficiency. Proc Natl Acad Sci U S A 89: 4028-4032.
36. Allikmets R, Raskind WH, Hutchinson A, Schueck ND, Dean M, et al. (1999) Mutation of a putative mitochondrial iron transporter gene (ABC7) in X-linked sideroblastic anemia and ataxia (XLSA/A). Hum Mol Genet 8: 743-749.
37. Guernsey DL, Jiang H, Campagna DR, Evans SC, Ferguson M, et al. (2009) Mutations in mitochondrial carrier family gene SLC25A38 cause nonsyndromic autosomal recessive congenital sideroblastic anemia. Nat Genet 41: 651-653.
38. Kiselyov K, Jennigs JJ Jr, Rbaibi Y, Chu CT, (2007) Autophagy, mitochondria and cell death in lysosomal storage diseases. Autophagy 3: 259-262.
39. Tessitore A, Pirozzi M, Auricchio A, (2009) Abnormal autophagy, ubiquitination, inflammation and apoptosis are dependent upon lysosomal storage and are useful biomarkers of mucopolysaccharidosis VI. Pathogenetics 2: 4.
40. Vazquez MC, Balboa E, Alvarez AR, Zanlungo S, (2012) Oxidative stress: a pathogenic mechanism for Niemann-Pick type C disease. Oxid Med Cell Longev 2012: 205713.
41. Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, et al. (2013) Mitochondria and quality control defects in a mouse model of Gaucher disease-links to Parkinson's disease. Cell Metab 17: 941-953.
42. Exner N, Lutz AK, Haass C, Winklhofer KF, (2012) Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences. EMBO J 31: 3038-3062.
43. Tritschler HJ, Packer L, Medori R, (1994) Oxidative stress and mitochondrial dysfunction in neurodegeneration. Biochem Mol Biol Int 34: 169-181.
44. Cardoso SM, Pereira CF, Moreira PI, Arduino DM, Esteves AR, et al. (2010) Mitochondrial control of autophagic lysosomal pathway in Alzheimer's disease. Exp Neurol 223: 294-298.
45. Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361: 1651-1661.
46. Mazzulli JR, Xu YH, Sun Y, Knight AL, McLean PJ, et al. (2011) Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146: 37-52.
47. Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, et al. (2004) Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 82: 192-207.
48. Xu YH, Sun Y, Ran H, Quinn B, Witte D, et al. (2011) Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol Genet Metab 102: 436-447.
49. Alexander WS, Hilton DJ, (2004) The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22: 503-529.
50. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, et al. (1999) Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10: 39-49.
51. Rylski M, Welch JJ, Chen YY, Letting DL, Diehl JA, et al. (2003) GATA-1-mediated proliferation arrest during erythroid maturation. Mol Cell Biol 23: 5031-5042.
52. Ferreira R, Ohneda K, Yamamoto M, Philipsen S, (2005) GATA1 function, a paradigm for transcription factors in hematopoiesis. Mol Cell Biol 25: 1215-1227.
53. Stachura DL, Chou ST, Weiss MJ, (2006) Early block to erythromegakaryocytic development conferred by loss of transcription factor GATA-1. Blood 107: 87-97.
54. Liew CW, Rand KD, Simpson RJ, Yung WW, Mansfield RE, et al. (2006) Molecular analysis of the interaction between the hematopoietic master transcription factors GATA-1 and PU.1. J Biol Chem 281: 28296-28306.
55. Gutierrez L, Lindeboom F, Langeveld A, Grosveld F, Philipsen S, et al. (2004) Homotypic signalling regulates Gata1 activity in the erythroblastic island. Development 131: 3183-3193.
56. Pevny L, Lin CS, D'Agati V, Simon MC, Orkin SH, et al. (1995) Development of hematopoietic cells lacking transcription factor GATA-1. Development 121: 163-172.
57. Yamaguchi Y, Ackerman SJ, Minegishi N, Takiguchi M, Yamamoto M, et al. (1998) Mechanisms of transcription in eosinophils: GATA-1, but not GATA-2, transactivates the promoter of the eosinophil granule major basic protein gene. Blood 91: 3447-3458.
58. Morceau F, Schnekenburger M, Dicato M, Diederich M, (2004) GATA-1: friends, brothers, and coworkers. Ann N Y Acad Sci 1030: 537-554.
59. Cantor AB, Orkin SH, (2002) Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene 21: 3368-3376.
60. Stopka T, Amanatullah DF, Papetti M, Skoultchi AI, (2005) PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin structure. EMBO J 24: 3712-3723.
61. Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, et al. (2003) RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood 101: 4333-4341.
62. Shivdasani RA, (2001) Molecular and transcriptional regulation of megakaryocyte differentiation. Stem Cells 19: 397-407.
63. Patel-Hett S, Wang H, Begonja AJ, Thon JN, Alden EC, et al. (2011) The spectrin-based membrane skeleton stabilizes mouse megakaryocyte membrane systems and is essential for proplatelet and platelet formation. Blood 118: 1641-1652.
64. Lalle M, Curra C, Ciccarone F, Pace T, Cecchetti S, et al. (2011) Dematin, a component of the erythrocyte membrane skeleton, is internalized by the malaria parasite and associates with Plasmodium 14-3-3. J Biol Chem 286: 1227-1236.
65. Randrianarison-Huetz V, Laurent B, Bardet V, Blobe GC, Huetz F, et al. (2010) Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-beta signaling at the bipotent erythro-megakaryocytic progenitor stage. Blood 115: 2784-2795.
66. Miccio A, Blobel GA, (2010) Role of the GATA-1/FOG-1/NuRD pathway in the expression of human beta-like globin genes. Mol Cell Biol 30: 3460-3470.
67. Harbour JW, Dean DC, (2000) Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2: E65-67.
68. Chiba T, Nagata Y, Kishi A, Sakamaki K, Miyajima A, et al. (1993) Induction of erythroid-specific gene expression in lymphoid cells. Proc Natl Acad Sci U S A 90: 11593-11597.
69. van den Akker E, van Dijk T, Parren-van Amelsvoort M, Grossmann KS, Schaeper U, et al. (2004) Tyrosine kinase receptor RON functions downstream of the erythropoietin receptor to induce expansion of erythroid progenitors. Blood 103: 4457-4465.
70. Drissen R, von Lindern M, Kolbus A, Driegen S, Steinlein P, et al. (2005) The erythroid phenotype of EKLF-null mice: defects in hemoglobin metabolism and membrane stability. Mol Cell Biol 25: 5205-5214.
71. Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM, (1997) Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. QJM 90: 19-25.
72. Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, et al. (1999) Cytokines in Gaucher's disease. Eur Cytokine Netw 10: 205-210.
73. Hollak CE, Evers L, Aerts JM, van Oers MH, (1997) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23: 201-212.
74. Michelakakis H, Spanou C, Kondyli A, Dimitriou E, Van Weely S, et al. (1996) Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. Biochim Biophys Acta 1317: 219-222.
75. Arinobu Y, Mizuno S, Chong Y, Shigematsu H, Iino T, et al. (2007) Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages. Cell Stem Cell 1: 416-427.
76. Tsuji S, (2010) Genetics of neurodegenerative diseases: insights from high-throughput resequencing. Hum Mol Genet 19: R65-70.
77. Roukos DH, (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices 7: 723-726.
78. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
79. Trapnell C, Pachter L, Salzberg SL, (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25: 1105-1111.
80. Roberts A, Pimentel H, Trapnell C, Pachter L, (2011) Identification of novel transcripts in annotated genomes using RNA-Seq. Bioinformatics 27: 2325-2329.
81. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I, (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-284.
82. Cameron AC, Trivedi PK (1998) Regression analysis of count data. Cambridge, UK; New YorkNYUSA: Cambridge University Press. xvii, 411 p.
83. Huang da W, Sherman BT, Lempicki RA, (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13.
84. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.